Sionna Therapeutics Files 8-K on Shareholder Vote Matters

Ticker: SION · Form: 8-K · Filed: Jun 13, 2025 · CIK: 2036042

Sentiment: neutral

Topics: 8-k, shareholder-vote

TL;DR

Sionna Therapeutics filed an 8-K on June 13th regarding shareholder votes from June 12th.

AI Summary

Sionna Therapeutics, Inc. filed an 8-K on June 13, 2025, reporting on matters submitted to a vote of security holders on June 12, 2025. The filing indicates the company is incorporated in Delaware and its principal executive offices are located at 21 Hickory Drive, Suite 500, Waltham, MA 02451.

Why It Matters

This filing is important for investors to understand any significant decisions or approvals made by Sionna Therapeutics' security holders, which could impact the company's future direction.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of matters voted on by shareholders and does not indicate any immediate financial or operational risks.

Key Players & Entities

FAQ

What specific matters were submitted to a vote of Sionna Therapeutics' security holders on June 12, 2025?

The filing states that matters were submitted to a vote of security holders on June 12, 2025, but does not detail the specific matters in the provided text.

When was the Form 8-K filed with the SEC?

The Form 8-K was filed on June 13, 2025.

What is the principal executive office address for Sionna Therapeutics, Inc.?

The principal executive offices are located at 21 Hickory Drive, Suite 500, Waltham, MA 02451.

In which state is Sionna Therapeutics, Inc. incorporated?

Sionna Therapeutics, Inc. is incorporated in Delaware.

What is the telephone number for Sionna Therapeutics, Inc.?

The registrant's telephone number is 617-819-2020.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 13, 2025 regarding Sionna Therapeutics, Inc. (SION).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing